A compilation of research working groups on drug utilisation across Europe

被引：7
作者：
Sabaté M. [1 ,2 ,3 ]
Pacheco J.F. [1 ,2 ,3 ]
Ballarín E. [1 ,2 ,3 ]
Ferrer P. [1 ]
Petri H. [4 ]
Hasford J. [5 ]
Schoonen M.W. [6 ]
Rottenkolber M. [5 ]
Fortuny J. [7 ]
Laporte J.-R. [1 ,2 ,3 ]
Ibáñez L. [1 ,2 ,3 ]
机构：
[1] Fundació Institut Català de Farmacologia, Barcelona 08035
[2] Servei de Farmacologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona
[3] Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Barcelona 08035
[4] Hoffmann-La Roche, Welwyn Garden City AL7 1TWLondon, 6 Falcon Way, Shire Park
[5] Institute for Medical Information Sciences, Biometry, Epidemiology Ludwig Maximillians Universität-München, 81377 Munich
[6] Center for Observational Research, Amgen, Ltd., Uxbridge, Middlesex, 1, Uxbridge Business Park, Sanderson Road
[7] Global Clinical Epidemiology Department, Novartis Pharma AG, 08013 Barcelona, Gran Vía Corts Catalanes
来源：
BMC Research Notes | / 7卷 / 1期
关键词：
Drug consumption; Drug utilisation; European network; National databases; Pharmacoepidemiology; Pharmacovigilance; Review;
D O I：
10.1186/1756-0500-7-143
中图分类号：
学科分类号：
摘要：
Background: The assessment of the benefit-risk of medicines needs careful consideration concerning their patterns of utilization. Systems for the monitoring of medicines consumption have been established in many European countries, and several international groups have identified and described them. No other compilation of European working groups has been published.As part of the PROTECT project, as a first step in searching for European data sources on the consumption of five selected groups of medicines, we aimed to identify and describe the main characteristics of the existing collaborative European working groups. Findings. Google and bibliographic searches (PubMed) of articles containing information on databases and other sources of drug consumption data were conducted. For each working group the main characteristics were recorded.Nineteen selected groups were identified, focusing on: a) general drug utilisation (DU) research (EuroDURG, CNC, ISPE'S SIG-DUR, EURO-MED-STAT, PIPERSKA Group, NorPEN, ENCePP, DURQUIM), b) specific DU research: b.1) antimicrobial drugs (ARPAC, ESAC, ARPEC, ESGAP, HAPPY AUDIT), b.2) cardiovascular disease (ARITMO, EUROASPIRE), b.3) paediatrics (TEDDY), and b.4) mental health/central nervous system effects (ESEMeD, DRUID, TUPP/EUPoMMe). Information on their aims, methods and activities is presented. Conclusions: We assembled and updated information on European working groups in DU research and in the utilisation of five selected groups of drugs for the PROTECT project. This information should be useful for academic researchers, regulatory and health authorities, and pharmaceutical companies conducting and interpreting post-authorisation and safety studies. European health authorities should encourage national research and collaborations in this important field for public health. © 2014 S abaté et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 15 条
  • [1] The Selection and Use of Essential Medicines (Report of the WHO Expert Committee, 2005 WHO Technical Report Series 2006
  • [2] 933)
  • [3] Hartzema A.G., Tilson H.H., Chan K.H., Pharmacoepidemiology and Therapeutic Risk Management, (2008)
  • [4] Drug Utilization Studies. Methods and Uses, (1993)
  • [5] Platt R., Madre L., Reynolds R., Tilson H., Active drug safety surveillance: A tool to improve public health, Pharmacoepidemiol Drug Saf, 17, pp. 1175-1182, (2008)
  • [6] Tannen R.L., Weiner M.G., Xie D., Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: Comparison of database and randomised controlled trial findings, BMJ, 27, (2009)
  • [7] Abbing-Karahagopian V., Kurz X., De Vries F., Van Staa T.P., Alvarez Y., Hesse U., Hasford J., Van Dijk L., De Abajo F.J., Weil J.G., Grimaldi-Bensouda L., Egberts A.C., Reynolds R.F., Klungel O.H., Bridging differences in outcomes of pharmacoepidemiological studies: Design and first results of the protect project, Curr Clin Pharmacol Curr Clin Pharmacol, (2013)
  • [8] Walley T., Folino-Gallo P., Barry M., Bruzzone M., Dejoncheere K., Rosian I., Schroder H., Tilson L., Vogler S., The EuroMedStat proposals on indicators for price and utilization, Italian Journal of Public Health, 3, pp. 15-21, (2006)
  • [9] CNC Drug Utilization Results
  • [10] Vander Stichele R.H., Elseviers M.M., Ferech M., Blot S., Goossens H., European Surveillance of Antimicrobial Consumption (ESAC): Data collection performance and methodological approach, British Journal of Clinical Pharmacology, 58, 4, pp. 419-428, (2004)
12